Varian Medical Systems, Inc.

Bayer Schering Pharma Ag

Varian Medical Systems International Ag

Varian Medical Systems Particle Therapy Gmbh & Co Kg

Bayer Healthcare LLC

Bayer Intellectual Property Gmbh

Siemens Healthineers International Ag

Varian Medical Systems Particle Therapy Gmbh

Bayer Pharma Aktiengesellschaft

Renate Parry

Douglas W Schneider

Gordon Parry

Richard N Harkins

Deborah Parkes

Eric Abel

Christel Smith

Timo K Koponen

Anthony Magliari

Michael Matthew Folkerts

Perttu Niemela

Reynald Vanderstraeten

Jessica Perez

Rajiv Dua

Matti Ropo

Alexander Katsis

Michiko Alcanzare

Stanley Mansfield

David Richard Light

Deepak Khuntia

Patrick Kupelian

Noboru Satozawa

Tara Renee Heitner Hansen

Swati Girdhani

Edward J Seppi

Stefan Steidl

Kirk McLean

Antje Kahnert

Ulrike Schubert

Doug Schneider

Marian Seto

Douglas Schneider

Tara Heitner

Kirk Mclean

A computing system comprising a central processing unit (CPU), and memory coupled to the CPU and having stored therein instructions that, when executed by the computing system, cause the computing system to execute operations to generate a radiation treatment plan. The operations include accessing a minimum prescribed dose to be delivered into and across the target, determining a number of beams and directions of the beams, and determining a beam energy for each of the beams, wherein the number of beams, the directions of the beams, and the beam energy for each of the beams are determined such that the entire target receives the minimum prescribed dose. A quantitative time-dependent model-based charged particle pencil beam scanning optimization is then implemented for FLASH therapy.

Model based PBS optimization for flash therapy treatment planning and oncology information system

Methods for treating tumors by administering FLASH radiation and a therapeutic agent to a patient with cancer are disclosed. The methods provide the dual benefits of anti-tumor efficacy plus normal tissue protection when combining therapeutic agents with FLASH radiation to treat cancer patients. The methods described herein also allow for the classification of patients into groups for receiving optimized radiation treatment in combination with a therapeutic agent based on patient-specific biomarker signatures. Also provided are radiation treatment planning methods and systems incorporating FLASH radiation and therapeutic agents.

Methods of use of ultra-high dose rate radiation and therapeutic agent

Embodiments of the present invention provide an integrated solution to radiotherapy treatment planning that enables accurate recording and accumulation of physical parameters as input (e.g., dose, dose rate, irradiation time per voxel, etc.). User-defined functions are evaluated to correlate the input parameters with 4D biological outcomes. The resulting biological parameters can be visualized as a biological outcome map to evaluate decisions, support decisions, and optimize decisions regarding the parameters of the radiotherapy treatment plan, for example, for supporting clinical trials and related clinical research.

System and method for biological treatment planning and decision support

The methods described herein allow for the classification of patients into groups for receiving optimized radiation treatment based on patient specific biomarker signature. The biomarker signature includes markers that have been shown to correlate with TGF-B expression and to be associated with tumor aggressiveness, radioresistance and poor prognosis. The markers play a key role in the epithelial-mesenchymal transition. The methods described herein provide the dual benefits of anti-tumor efficacy plus normal tissue protection when combining TGF-B inhibitors with ionizing radiation to treat cancer patients.

Biomarkers for radiation treatment

An apparatus to examine a target in a patient includes an x-ray source configured to deliver a first x-ray beam towards the target, a device having an array of openings, the device located at an angle less than 180 degrees relative to a beam path of the first x-ray beam to receive a second x-ray beam resulted from an interaction between the first x-ray beam and the target, and a detector aligned with the device, the detector located at an angle less than 180 degrees relative to the beam path of the first x-ray beam to receive a part of the second x-ray beam from the device that exits through the openings at the device.

Functional and physical imaging using radiation

The methods described herein allow for the classification of patients into groups for receiving optimized radiation treatment based on patient specific biomarker signature. The biomarker signature includes markers that have been shown to correlate with TGF-&#x3b2; expression and to be associated with tumor aggressiveness, radioresistance and poor prognosis. The markers play a key role in the epithelial-mesenchymal transition. The methods described herein provide the dual benefits of anti-tumor efficacy plus normal tissue protection when combining TGF-&#x3b2; inhibitors with ionizing radiation to treat cancer patients.

The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for the membrane-anchored, 4O.kDa mesothelin polypeptide, which is overexpressed in several tumors, such as pancreatic and ovarian tumors, mesothelioma and lung cancer cells. These antibodies, accordingly, can be used to treat these and other disorders and conditions. Antibodies of the invention also can be used in the diagnostics field, as well as for further investigating the role of mesothelin in the progression of disorders associated with cancer. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.

Anti-mesothelin antibodies and uses thereof

Dimeric molecular complexes useful for diagnostics and therapeutics.

Dimeric molecular complexes

The present invention relates to novel human extracellular matrix polypeptides, designated RG1, polynucleotides encoding the polypeptides, methods for producing the polypeptides, expression vectors and genetically engineered host cells for expression of the polypeptides. The invention further relates to antibodies directed against the polypeptides and to methods for using the polynucleotides, and polypeptides, and antibodies in research, diagnosis, and therapeutic applications.

Isolated human antibodies that bind epitopes on RG1

Methods for treating disease-states associated with RG1 using immunoconjugates

The present invention relates to antibodies, and antigen-binding antibody fragments, directed against an RG1 polypeptide. The invention further relates to methods for utilizing the antibodies, and antibody fragments, for diagnostic and therapeutic applications.

RG1 antibodies and uses thereof

Growing community of inventors

Oakland, CA, United States of America

Renate Parry